Metformin-induced weight loss in patients with or without type 2 diabetes/prediabetes: A retrospective cohort study
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Obesity Research & Clinical Practice
- Vol. 15 (1) , 64-68
Abstract
No abstract availableKeywords
Funding Information
- Sanofi
- Janssen Pharmaceutica
- Eli Lilly and Company
- Novo Nordisk
- Pfizer
This publication has 15 references indexed in Scilit:
- Metformin: an Old Therapy that Deserves a New Indication for the Treatment of ObesityCurrent Atherosclerosis Reports, 2016
- Food Order Has a Significant Impact on Postprandial Glucose and Insulin LevelsDiabetes Care, 2015
- The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes PreventionDiabetes Care, 2012
- Long-Term Persistence of Hormonal Adaptations to Weight LossNew England Journal of Medicine, 2011
- Advantages of Extended-Release Metformin in Patients with Type 2 Diabetes MellitusPostgraduate Medicine, 2011
- An RCT of metformin versus orlistat for the management of obese anovulatory womenHuman Reproduction, 2008
- Metformin and body weightInternational Journal of Obesity, 2007
- Efficacy, Tolerability, and Safety of a Novel Once-Daily Extended-Release Metformin in Patients With Type 2 DiabetesDiabetes Care, 2006
- Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studiesDiabetes, Obesity and Metabolism, 2004
- Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesityDiabetes, Obesity and Metabolism, 2002